David Goeddel (born 1951 in San Diego) is a pioneer of the biotechnology industry who, employed at the time by Genentech, successfully used genetic engineering to coax bacteria into creating synthetic human insulin, human growth hormone, and human Tissue plasminogen activator (tPA) for use in therapeutic medicine.
Dr. James Grotta was principal investigator in Houston for the first major trial showing benefits of clot-busting drug Tissue Plasminogen Activator (tPA).
rtPA may refer to Recombinant tissue plasminogen activator, a protein involved in the breakdown of blood clots.
Continuous erythropoietin receptor activator | Tissue plasminogen activator | Tissue paper | Granulation tissue | Tissue Plasminogen Activator | tissue paper | Tissue factor | Plant tissue culture | plant tissue culture | '''Masson's trichrome''' stain of rat airway. Connective tissue | Irving Tissue | Human Tissue Resource Network | Guided bone and tissue regeneration | Gamgee Tissue | Enzyme activator | Brown adipose tissue | APC/C activator protein CDH1 |